Vanguard Group Inc Delcath Systems, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,610,735 shares of DCTH stock, worth $17.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,610,735
Previous 1,394,028
15.55%
Holding current value
$17.9 Million
Previous $17.7 Million
23.44%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding DCTH
# of Institutions
121Shares Held
13.2MCall Options Held
105KPut Options Held
38.7K-
Deerfield Management Company, L.P. (Series C) New York, NY813KShares$9.02 Million0.25% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il803KShares$8.92 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA703KShares$7.81 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA570KShares$6.32 Million1.64% of portfolio
-
Marshall Wace, LLP London, X0483KShares$5.36 Million0.01% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $95.4M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...